See the new 2009 ASH abstracts
Non-Hodgkin's Lymphoma Cyberfamily Home
Table of contents
- Alternative Donor Transplantation Poster
- Biologic Therapies for NHL (Excluding Pre-clinical Models
- Clinical Care - Transplantation Regimen Toxicities and Engraftment
- Clinical Results - Allogeneic Matched Related Donor Transplantation
- Clinical Transplantation – Acute and Chronic GVHD, Infectious Complications,
and Immune Reconstitution
- Experimental Transplantation - GVHD and GVL
- Lymphoma: Chemotherapy and Clinical Trials
- Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents
- Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy
- Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment
1
- Clinical Transplantation: Acute GVHD Prevention and Risk Assessment
- Alternative Donor Transplantation
- Biologic Therapies for NHL (Excluding Pre-clinical Models)
- Clinical Care - Recurrence, Secondary Neoplasia, and Late Complications after
Transplantation
- Clinical Care - Transplantation Regimen Toxicities and Engraftment
- Clinical Results - Allogeneic Matched Related Donor Transplantation
- Clinical Results - Autologous Transplantation
- Clinical Transplantation – Acute and Chronic GVHD, Infectious Complications,
and Immune Reconstitution
- Experimental Transplantation - Basic Biology, Immune Function, and
Engraftment
- Experimental Transplantation - GVHD and GVL
- Lymphoma: Chemotherapy and Clinical Trials
Poster II
- Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster II
- Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy Poster II
- New and Emerging Biologic Therapies of NHL
- Targeted Therapies and New Agents in Lymphoma
- Clinical Results - Allogeneic Matched Related Donor Transplantation I
- Mantle Cell Lymphoma, Follicular Lymphoma, Tumor Microenvironment
- Clinical Results - Allogeneic Matched Related Donor Transplantation II
- Diffuse Large B-cell Lymphoma: Biology and Prognosis
- Clinical Studies in Lymphoma
- DLBCL and Other NHL: Novel Therapeutic Targets and Approaches
- Low Grade B-cell Lymphoma: Biology
- Alternative Donor Transplantation Poster III
- Biologic Therapies for NHL (Excluding Pre-clinical Models) Poster III
- Clinical Results - Allogeneic Matched Related Donor Transplantation Poster
III
- Clinical Results - Autologous Transplantation Poster III
- Experimental Transplantation - GVHD and GVL Poster III
- Lymphoma: Chemotherapy and Clinical Trials Poster III
- Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy Poster III
- Autologous Transplantation: Lymphoma
- Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment
2
- Diffuse Large B-cell Lymphoma: Molecular Biology
- Incorporation of Rituximab into Clinical Management of NHL
- Preclinical Studies in NHL: Novel Antibodies and Immunotherapeutic Approaches
Alternative donor transplantation I
965 One
Antigen HLA-Mismatched Related and 8/8 Allele Matched Unrelated Donors Are
Associated with Similar Survival after Hematopoietic Cell Transplantation for
Acute Leukemia
966
Comparable Results of HLA-Mismatched Vs HLA-Matched Unrelated Donors for
Allogeneic Stem Cell Transplantation Using Pre-Transplant ATG
967 Clinical
and Cost Outcomes of Double Umbilical Cord Blood Versus Bone Marrow and
Peripheral Blood Unrelated Hematopoietic Stem Cell Transplants
968 Decreased
Relapse Rates without Excessive Transplant Related Mortality Following Cord
Blood Transplantation (CBT): A Matched Cohort Analysis Comparing Myeloablative
Cord, Matched Unrelated, and Mismatched Unrelated Donor Transplants
969 Unrelated
Transplants for Poor Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term
Comparative Analysis Based on the Hematopoietic Progenitor Source
970
Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic
Myelogenous Leukemia in the Imatinib Era
971 Unrelated
Bone Marrow Transplantation for Children with Chronic Myeloid Leukemia (CML): A
Report from the Japan Marrow Donor Program (JMDP)
972
Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell
Transplantation for Chronic Lymphocytic Leukemia
973 Results
of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Advanced
Chronic Myeloid Leukemia (CML) Patients (pts) Who Failed Tyrosine Kinase
Inhibitors (TKIs) after Developing BCR-ABL Kinase Domain (KD) Mutations
974
Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients
with Peripheral T-Cell Lymphoma
975 Salvage
Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for
Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with
Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study
976 Treatment
of AML in First Remission (CR1) with Allogeneic Hematopoietic Stem Cell
Transplantation (HSCT) Using Unrelated Donors (UD)
977 Risks and
Benefits of Unrelated Donor Peripheral Blood Progenitor Cells (PBPC) in Children
and Adolescents with Acute Leukemia
978 Upfront
Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute
Myeloid Leukemia Patients within the Randomized Multi-Center Trial AML2003
979 Long-Term
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in
Patients (pts) with Advanced Chronic Myeloid Leukemia (CML) Post Imatinib
Failure
Biologic Therapies for NHL (Excluding Pre-clinical Models
1000 A
Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell
Lymphoma
1001 Elderly
Patients with Mantle Cell Lymphoma (MCL) – Efficacy and Feasibility of Prolonged
Immunochemotherapy with Rituximab, Cytarabine and Fludarabine Added to CHOP and
Followed by Rituximab Maintenance Treatment. A Prospective Study by the Finnish
Lymphoma Group
1002 A Phase
I/II Study of IPH1101 (BrHPP), Specific Agonist of Vγ9Vδ2 T Lymphocytes, in
Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma.
Interim Phase I Data
1003 FLIPI
Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB
50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80
monoclonal antibody) Plus Rituximab [R]
1004 Durable
Responses in Patients Treated with Galiximab (Anti‑CD80) in Combination with
Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of
a Phase II Clinical Trial
1005 Phase II
Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell
Lymphoma (CTCL)
1006 Multiple
Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug
Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas
1007 Phase I
Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts)
with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL):
Updated Results
1008 CNTO
328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in
Castleman’s Disease: Preliminary Results of a Phase I Study
1009 A Phase
I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with
B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease
1010 Final
Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in
Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM)
1011 Phase
II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom
Macroglobulinemia: The Dana Farber Cancer Institute Experience
1012
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the
Treatment of Advanced Follicular Lymphoma Patients
1013 Final
Results of a Phase II Danish Trial Testing Low Dose Total Body Irradiation
Following Six Bi-Weekly RCHOP-14 Plus 2 Extra Rituximab in Elderly High risk
Patients with Aggressive CD20+ Diffuse Large B-Cell Lymphoma (DLBCL)
1014 The
Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of
Subsequent Responses. the Analysis on Behalf of CLS
Clinical Care - Transplantation Regimen Toxicities and Engraftment
1115 The
Effect of Increasing CD34+ Cell Doses on Time to Engraftment after
Autotransplantation for Hematologic Malignancies
1116
Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic
Cell Transplantation (HCT)
1117 Clinical
Outcomes and Pharmacokinetics of Targeted Intravenous Busulfan in Children
Receiving Stem Cell Transplantation for Thalassemia
1118
Optimizing the CD34+ Cell Dose for Allogeneic Transplantation
1119 The
Hematopoietic Cell Transplantation Comorbidity Index: No Effect on Outcome of
Reduced-Intensity Allografts
1120 Febrile
Reactions Occurring with Second Cycle of High Dose Melphalan and Stem Cell
Transplantation in Patients with AL Amyloidosis: A “Melphalan Recall”
Reaction
1121 Prior
Treatment with Chemotherapy Associated to Gemtuzumab Ozogamicin (GO) Does Not
Increase the Risk of Veno-Occlusive Disease (VOD) after Allogeneic Stem Cell
Transplantation (all-SCT)
1122
Danapaloid Is Significantly Effective for the Prophylaxis of Hepatic Veno-Occlusive
Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study
of 85 Children with Hematological Malignancies
1123 Wireless
Video-Capsule Endoscopy Is a More Sensitive Investigative Method Than
Gastro-Intestinal Endoscopy and Biopsies for the Diagnosis of Acute GI-Gvhd
1124 Outcomes
of Pediatric Patients with Respiratory Failure Following Hematopoietic Cell
Transplant (HCT); 8 Years' Experience with High Frequency Oscillatory
Ventilation (H
Clinical Results - Allogeneic Matched Related Donor Transplantation
1125
Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Versus Conventional
Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) and High-Risk
Myelodysplastic Syndrome (MDS) Attaining Complete Remission (CR1) Post Induction
Chemotherapy: a Retrospective Case Control Study
1126
Long-Term Follow-up Results of IFM9903 and IFM9904 Trials Comparing Non
Myeloablative Allotransplantation with Autologous Transplantation in High-Risk
De Novo Multiple Myeloma
1128
Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST)
in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict
Survival
1129 Outcome
after Allogeneic Stem Cell Transplantation for Adult Acute Myeloid Leukaemia
Patients Exhibiting Isolated or Associated Trisomy 8 Chromosomal Abnormality: A
Survey on Behalf of the Acute Leukemia Working Party (ALWP) of the EBMT
1130 Tandem
Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients
1131
Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC
Experience
1132
HLA-Identical Allogeneic Stem Cell Transplantation (alloSCT) for Patients with
Primary Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Analysis of the
Lymphoma Working Party of the European Group for Blood and Marrow
Transplantation (EBMT-LWP)
1133 Use of
the Propensity Score Matching Method to Reduce Recruitment Bias in Observational
Studies: Application to the Estimation of Survival Benefit of Non-Myeloablative
Allogeneic Transplantation In Patients with Multiple Myeloma Relapsing
after a First Autologous Transplantation
1134
Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic
Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or
MDS: A Dose and Schedule Finding Study
Clinical Transplantation – Acute and Chronic GVHD, Infectious Complications,
and Immune Reconstitution
1145
Relationships Between Late Viral Infections and Immune Reconstitution after
Hematopoietic Stem Cell Transplantation
1146 Immune
Reconstitution Following Myeloablative Allogeneic Hematopoietic Stem Cell
Transplantation: The Impact of Expanding CD28negCD8+ T-Cells on Relapse
1147 Impact
of Prior Invasive Pulmonary Aspergillosis (IPA) on Outcome in Patients Receiving
Reduced Intensity Conditioning (RIC) Allogeneic Haematopoietic Stem Cell
Transplantation (Allo-SCT)
1148 Features
of Herpesviruses (CMV, EBV, HHV6) Infections and Immune Reconstitution after
Allogeneic Stem Cell Transplantation (allo-SCT) Using Alternative Donors:
Comparison Between Matched Unrelated Donors (MUD) and Cord Blood (CB) as Stem
Cell Source
1149 An Early
CT-Diagnosis Based Treatment Strategy for Invasive Fungal Infection in
Allogeneic Transplant Recipients Using Caspofungin First Line: An Effective
Strategy with Low Mortality
1150 Impact
of Cyclosporine a (CsA) Concentration on the Incidence of Severe Acute
Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT)
1151
Antithymocyte Globulins (ATG) as Part of the Myeloablative Conditioning (MAC)
Regimen Can Reduce the Risk of Severe Graft-Vs.-Host Disease (GVHD) after
Allogeneic Stem Cell Transplantation (allo-SCT) from Matched-Unrelated Donors
(MUD)
1152
Incidence and Risk of Post-Herpetic Neuralgia after Varicella Zoster Virus (VZV)
Infection in Hematopoietic Cell Trasnplantation (HCT) Recipients
1153
Cyclosporine dose Intensity Is a Critical Determinant of Outcome after a T Cell
Depleted Reduced Intensity Allograft
1154 Use of a
Potassium Channel Blocker to Inhibit Effector-Memory T Cells Isolated from
Recipients of Allogeneic BMSCT
1155 Delayed
Cytomegalovirus (cmv) Infection Following Hematopoietic Cell Transplantation
(HCT): City of Hope (COH) Experience
1156 Phase 1
Clinical Study of Adoptive Immunotherapy with Delayed Infusion of Alloanergized
Donor T Cells to Improve Immune Reconstution after Haploidentical Stem Cell
Transplantation
1157 Adoptive
Immunotherapy after Haploidentical Stem Cell Transplantation with T Cells
Allodepleted by Photodynamic Purging
1158 A Phase
I/II Trial of Bortezomib, Tacrolimus and Methotrexate for Prophylaxis of Acute
Graft Versus Host Disease after HLA Mismatched Reduced Intensity Transplantation
1159
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infection in
Allogeneic Stem Cell Transplant Recipients: Results of the VOSIFI Study. on
Behalf of the VOSIFI Study Group and the Infectious Diseases Working Party of
the European Bone and Marrow Transplantation Group
1160 Clinical
Significance of Serum Hepcidin-25 Levels on Early Treatment-Related
Complications after Hematopoietic Stem Cell Transplantation
1161 The
Pattern of KIR Ligands in Adult Patients with AML Is Associated with Various
Post-Transplant Complications, Including GvHD after HLA-Matched Sibling or
Unrelated Donor Transplantation
1162
Monitoring of Adenovirus Load in Stool by Real-Time PCR Permits Early Detection
of Impending Invasive Infection in Patients after Allogeneic Stem Cell
Transplantation
1163
Immunogenicity of the Tetravalent Protein-Conjugated Meningococcal Vaccine in
Recipients of Related and Unrelated Allogeneic Hematopoietic Cell
Transplants (HCT)
1164 Initial
Liver Involvement in Acute Graft-Versus-Host Disease (GVHD) Predicts a Severe
Acute Gvhd and Poor Long-Term Survival
1165
SELDI-TOF-Based Proteomic Analysis of Plasma Samples as a Diagnostic Tool to
Predict Acute Graft-Versus-Host Disease after Allogeneic Stem Cell
Transplantation
1166 Bone
Marrow Reaction in Chronic Graft-Versus-Host Disease
1167
Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults
Depends on Reconstitution of Thymopoiesis and Regeneration of NAÏVE CD8+ T Cells
1168
Selective Allodepletion by TH9402-Mediated Photosensitization Results in Early
Full Donor T Cell Reconstitution in the Absence of High-Grade, Acute GvHD and Is
Associated with Favorable Outcome after HLA Matched Sibling SCT for Hematologic
Malignancies
1169 IgG
Antibodies against Human Cytomegalovirus Late Protein UL94 in the Pathogenesis
of Scleroderma-Like Skin Lesions in Chronic Graft Versus Host Disease
1170
Randomized Phase II Trial Comparing Cyclosporine (CSP) and Tacrolimus (TAC) for
Methotrexate (MTX)-Free Graft-Versus-Host Disease (GVHD) Prophylaxis after
Allogeneic Transplantation from a Matched Related Donor (MRD) with a
Reduced-Intensity Regimen Containing Cladribine and Busulfan
1171 Human
Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe
and Effective For the Treatment of Graft Versus Host Disease
1172 Graft
Versus Host Disease (GVHD) Prophylaxis with Everolimus and Tacrolimus Is
Associated with a High Incidence of Sinusoidal Obstruction Syndrome and
Microangiopathy – Results of the EVTAC Trial
1173
Long-Term T Cell Immune Reconstitution in Patients Surviving 10 or More Years
after Allogeneic Stem Cell Transplantation for Hematologic Malignancies
1174 Catheter
Related Bloodstream Infection in Haematological Patients: A Prospective,
Randomized Study Comparing Heparin-Coated with Chlorhexidine and Silver
Sulfadiazine Impregnated Central Venous Catheters
1175 Immune
Reconstitution after Haploidentical Hematopoietic Cell Transplantation: Impact
of Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts
1176
Graft-Versus-Host Disease (Gvhd) Prophylaxis with Tacrolimus and Mycophenolate
Mofetil (MMF) in 131 Matched Sibling Nonmyeloablative (NMA) Transplant
Recipients: Long-Term Follow-up Confirms Extremely Low Incidence of Acute (a)
Gvhd, High Incidence of Extensive Chronic (c) Gvhd and Favorable Disease Outcome
1177 T Cell
Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia
but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation
1178
Macrophage Infiltration of Skin Lesions Correlates to Prognosis of Gvhd; A Clue
to Refractory Gvhd
1179
Thrombotic Microangiopathy in Patients with Allogeneic Hematopoietic Stem Cell
Transplantation
1180
Autoantibody Production during Chronic Graft-Versus-Host Disease Does Not
Associate with Long-Term Persistence of Host B Cells in Humans
1181 Adoptive
Transfer and Consequential Selective Reconstitution of Streptamer-Selected
Cytomegalovirus- Specific CD8+ T Cells Leads to Enduring Virus Clearance in
Patients after Allogeneic Stem Cell Transplantation
1182
Reconstitution of CD52-Negative CD4 T Cells after Alemtuzumab-Based T Cell
Depleted Allogeneic Hematopoietic Stem Cell Transplantation
1183 Higher
Numbers of Circulating Dendritic Cells and T-Cells Predict Response to
Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease
1184
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN)
in patients with chronic Graft-Versus-Host Disease
Experimental Transplantation - GVHD and GVL
1245 Human
Alloreactive CD4+ T Cells as Potent Effector Cells and Sole Mediators of
Anti-Tumor Responses in a NOD/SCID Mouse Model for Human Acute Leukemia
1246
MHC-Matching at 5 Loci Results in Higher Levels of Engraftment of Allogeneic
Cord Blood (CB) Hematopoietic Stem Cells (HSC) Following Neonatal
Transplantation
1247
Characterization of Cytotoxic T Lymphocyte Clones Isolated from Bone Marrow
Transplant Recipient with HLA-Cw-Mismatched Donor
1248 Blocking
of IL-21 Signal Attenuates Graft-Versus-Host Disease but Not
Graft-Versus-Leukemia Effect in a Mouse Model
1249
Molecular Identification of Individual T Cell Clones Specific for
Graft-Versus-Leukemia Reaction
1250
Interleukin-17-Producing T Cells: A New Potential Player Mediating Graft Versus
Host Pathology In Patients Undergoing Allogeneic Stem Cell Transplantion
1251
Immunomodulatory Effects of Vitamin D: Implications for the Prevention and
Treatment of Graft Versus Host Disease
1252 CD11b-
Donor Dendritic Cells Enhance Donor T-Cells' Th1 Polarization and Graft Versus
Leukemia Activity in Allogeneic Hematopoietic Stem Cell Transplantation
1253 Donor
Single Nucleotide Polymorphism in the CCR9 Gene Affects the Incidence of Acute
Skin Graft-Versus-Host Disease
1254
Methylation in the Promoter Region and Expression of FOX-P3 Correlate with Graft
Versus Host Disease, Relapse and Survival after Allogeneic Stem Cell
Transplantation
Lymphoma: Chemotherapy and Clinical Trials
1557 Human
Herpesvirus 8 Protein K1 Interference with Fas-Mediated Apoptosis Induces Clonal
Growth Which Leads to Lymphoid Hyperplasia
1558 Eight
Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed
by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in
Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12
Trial of the German Hodgkin Study Group (GHSG)
1559
Supportive Efficacy Analyses for the Phase 3 Study of Temsirolimus Versus
Investigator's Choice Therapy for the Treatment of Patients with Relapsed or
Refractory Mantle Cell Lymphoma
1560 The
Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle
Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II
Studies (NHL-002 and NHL-003)
1561
Farnesyltransferase Inhibitor Tipifarnib (Zarnestra) in Refractory Mantle Cell
Lymphoma (MCL): A Therapeutic Target Only for Specific Patients Categorized by
the 2-Gene Classifier for Predictive Response to Tipifarnib
1562 A Phase
II Trial of Darinaparsin in Advanced Lymphomas: Report on Safety and Activity
1563 A Phase
I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Administered
on Days 1 and 15 Every 28 Days without and with Prophylactic G-CSF in
Non-Hodgkin or Hodgkin Lymphoma
1564 A Phase
2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed
or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium
Study
1565 Phase I
and Pharmacokinetic Study of Inotuzumab Ozogamicin (CMC-544) as a Single Agent
in Japanese Patients with Follicular Lymphoma Pretreated with Rituximab
1566
Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis
from An Ongoing Multicenter Phase II Trial
1567 Results
of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed
Peripheral T-Cell Lymphoma (PTCL)
1568 Final
Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent
Cutaneous T-Cell Lymphoma (Molecular Analyses Included)
1569
Pralatrexate (PDX) IS Active in Cutaneous T-Cell Lymphoma: Preliminary Results
of a Multi-Center Dose-Finding Trial
1570 A Phase
1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed
or Refractory Lymphoproliferative Malignancies
1571
Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent
B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma
1572 Results
of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory
Indolent Lymphoma
1573 Phase I
Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with
Recurrent or Refractory Indolent B-Cell Neoplasms
1574 Weekly
Treatment with a Combination of Bendamustine and Bortezomib in Relapsed or
Refractory Indolent Non-Hodgkin’s Lymphoma: A Single-Center Phase 1/2 Study
1575 Interim
Results of the RiPAD+C Regimen Including Velcade in Front Line Therapy for
Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the
GOELAMS Group
1576
Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated
Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the
NCIC Clinical Trials Group
Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents
1577
Complement (C) Activation Followed by Penetration of the Membrane Attack Complex
(MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which
Induces Streamers. Generalization of Streaming to Include other Mabs and Target
Cells
1578 Binding
of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or
Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and
Considerably Higher Levels of CDC Are Induced by OFA Than by RTX
1579 A Novel
mTOR Kinase Inhibitor Causes Growth Inhibition, Cell Cycle Arrest, Apoptosis and
Autophagic Cell Death in Mantle Cell Lymphoma Cell Lines: A Distinct Profile
from Rapamycin
1580
Characterization of MDX-1401, a Human Anti-CD30 Antibody with Enhanced Effector
Function, for Therapy of Malignant Lymphoma
1581 T Cell
Modulation Combined with Intratumoral CpG Cures Lymphoma without the Need for
Chemotherapy
1582 IL-10
Present in the B Lymphoma Microenvironment Drives Macrophages to Efficient
Tumour Suppressing Cells with High Phagocytic Activity in Presence of Rituximab
1583
Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal
Antibody, with Rituximab in Non-Hodgkin Lymphoma
1584 A
Promising Therapeutic Implication of a Novel Bcl-2 Family Inhibitor ABT-737 for
Adult T-Cell Leukemia/Lymphoma
1585 Compared
Antitumor Activity of GA101 and Rituximab against the Human RL Follicular
Lymphoma Xenografts in SCID Beige Mice
1586 Combined
Treatment with Short Synthetic Anti-Lymphoma Peptide and CpG ODN; A Therapeutic
Vaccine Which cures the A20 Lymphoma in Balb/C Mice
1587 The
Histone Deacetylase Inhibitor Vorinostat Induces Apoptosis in T-Cell Lymphoma
Cell Lines and Synergizes with Bortezomib
1588
Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing
Toxicity by Combination with Antibody immunotherapy
1589 In-Vitro
Treatment with the AKT-Inhibitor GSK 690693 Induces Cell Death in Lymphoma Cell
Lines and in Primary CLL Cells and Is Followed by Caspase-3 Activation and
Cytochrome C Release
1590 A Novel
Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo
Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method
1591
Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity
1592
Anti-Tumor Activity of the Aurora a Inhibitor MLN8237 in Diffuse Large B-Cell
Lymphoma Preclinical Models
1593
Identification of a Diagnostic Gene Signature for SGN-40, Anti-CD40 Monoclonal
Antibody, in Pre-Clinical NHL Models and the Role of FAS in SGN-40 Mediated
Apoptosis
1594
Cytotoxic Activity of Histone Deacetylase Inhibitor ITF2357 on Burkitt's
Lymphoma Cell Lines Is Associated to Micro-RNA Modulation and Transglutaminase 2
Restoration
1595
Inhibition of Human Lymphoma Cell Growth by the PKC-Beta Selective Inhibitor
Enzastaurin (LY317615) in Combination with Multiple Therapeutic Agents
1596
Molecular Mechanism by Which Rituximab Sensitizes B-NHL Cells to TRAIL
Apoptosis: Induction of RKIP and DR5 Expression Via Inhibition of NF-Kb, Snail,
and YY1
Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy
1763
Absolute Lymphocyte Count at the Time of Relapse Predicts Survival in Patients
with Diffuse Large B-Cell Lymphoma
1764 Rac1
GTPase Targeting Inhibits p53-Deficiency Mediated Lymphomagenesis
1765 Analysis
of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145
Mantle Cell Lymphoma Cases with An Abnormal Karyotype
1766
Proteomic Analysis of Chronic Malignant B-Cell Derived Microparticles Reveals
CD148 as a Potential Antigenic Marker for Mantle Cell Lymphoma Diagnosis
1767
Targeting CDK4 in Mantle Cell Lymphoma (MCL) Cell Lines by Specific Lentiviral
shRNA Mediated Knockdown Has Profound Effects on Cell Growth and Cell Cycle but
Minimal Effects on Apoptosis
1768
Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF]
and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with
Non-Hodgkin Lymphoma
1769 Genome
Wide Analysis of 41 Mycosis Fungoides Tumor Stage Using Array Comparative
Genomic Hybridization Technology
1770
Incidence and Clinicopathological Relevance of Gene Copy Number
Abnormalities Detected by a Single Quantitative PCR Assay in Mantle Cell
Lymphomas
1771
Deletions of Chromosomes 6q and 13q, and Trisomy 4 Are the Most Common
Cytogenetic Abnormalities in Waldenstrom Macroglobulinemia. Preliminary Results
of a Multicentric Study
1772 Low
Ratio of Inter-Follicular CD8/FOXP3-Positive Regulatory T-Cells Is Associated
with a favourable Overall Survival in Follicular lymphoma (FL)
1773 In
Follicular Lymphoma (FL), γδt-Lymphocytes (γδT) Are Present and Expandable from
Peripheral Blood and Rare in Tumour Lymph Nodes, Mostly in Peri-Follicular Areas
1774
Proteomic Analysis for the Identification of Disease Biomarkers and Therapeutic
Targets in Natural Killer Cell Lymphoma
1775 Splenic
Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain
Repertoires
1776 Outcomes
and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders
(PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the
Post-Rituximab Era
1777 Family
History of Cancer and Risk of Lymphoma: Influence of IL8RB, GGH IVS7 and IL10
Polymorphisms
1778 IgG-Secreting
B-Cell Lymphoplasmocytoid Leukaemia : Molecular Characterization of Igh
Rearrangements
1779 CS-1 Is
Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell
Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63)
1780 Indolent
Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological
Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase
Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis
1781 Clinical
Significance of CD21 Co-Expressed with LFA-1 in Non-Hodgkin’s B-Cell Lymphoma
1782
Clinicopathologic Analysis of Primary Gastrointestinal T-Cell Lymphoma with a
Special Reference to Intestinal and Gastric Type in Japan
1783 Vitamin
D, Sun Exposure, and Lymphoma Risk
1784 A
Critical Analysis of Prognostic Factors in Patients with HTLV-1 Adult T-Cell
Leukemia/Lymphoma: A Multicenter Clinicopathologic Experience and New Prognostic
Score
1785
Cutaneous Lymphocyte Antigen and TRAF-1 Are Useful in Differentiating
Lymphomatoid Papulosis, Cutaneous ALCL and Systemic ALCL
1786 Loss of
CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not
Explained by Methylation of CIITA Promoters III and IV
1787
Expression of CD20 but Not EBV Is Associated with Significantly Improved Overall
(OS) and Event Free Survival (EFS) in Children with Post Transplant
Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT)
Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment
1
49
Treatment-Related Mortality and Relapse Rate from Time of Initiation of
Post-Remission Therapy for Patients Receiving Allogeneic Transplantation,
Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern
Cooperative Oncology Group (ECOG)
50 Polyoma
(BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
from Donors Other Than Matched Siblings: A Prospective Evaluation of Hemorrhagic
Cystitis (HC) Incidence
51 Obesity
Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell
Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults
52 Clinical
and Genetic Factors Underlying Acute Bone Mineral Density Loss by 100 Days after
Blood and Marrow Transplantation: A Potential Early Regimen-Related Complication
53
Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose
Melphalan and Stem Cell Transplantation: Trend Over the Past 14 Years at a
Single Institution
54
Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic
Stem Cell Transplantation : A Prospective Randomized Multicenter Trial
Clinical Transplantation: Acute GVHD Prevention and Risk Assessment
55 BMT CTN
0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil
(MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids
in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD)
56
Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent
for Prevention of Acute and Chronic Graft Versus Host Disease after
Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation
(BMT)
57 A
Randomized Prospective Multicenter Phase III Trial Comparing Standard GvHD
Prophylaxis with Cyclosporine and Methotrexate with Additional Pretransplant ATG
Fresenius (ATG-F) in Allogeneic Stem Cell Transplantation from Matched Unrelated
Donors
58
Donor-Recipient Mismatches in MHC Class I Chain-Related Gene a (MICA) in
Unrelated Donor (UD) Transplantation
59 Impact of
Highly Conserved HLA Haplotype on Acute Graft-Versus-Host Disease in Unrelated
Bone Marrow Transplantation
60 Minor
Histocompatibility Antigen Mismatches and Graft Versus Host and Relapse in
High-Resolution HLA-Matched Allogeneic Hematopoietic Stem Cell Transplantation
Alternative Donor Transplantation
1957
Favorable Leukemia-Free Survival (LFS) for Adults and Children Undergoing
Myeloablative Umbilical Cord Blood (UCB) Transplantation with Cyclophosphamide
(CY), Fludarabine (FLU) and Total Body Irradiation (TBI): A Single Center
Analysis of 194 Patients
1958 High
Rate of Second Malignancies after Reduced Intensity Double Cord Blood
Transplants in Adults
1959
Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced
Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation
in Patients with Advanced Indolent Non-Hodgkin Lymphoma: Interim Analysis of a
Phase II Study
1960
Prospective Phase II Study of Biologic Assignment One Vs Two Unit Umbilical Cord
Blood Transplant (UCBT) in the Reduced-Intensity Conditioning Setting
1961 Direct
Intra-Bone Cord-Blood Transplantation Overcomes the Problem of Graft Failure
Even When Low Numbers of HLA-Mismatched Cord-Blood Cells Are Transplanted, Thus
Leading to the Possibility of Use of This Technique in a Large Number of
Patients
1962
Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults Using
Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Interim Analysis of
a Phase I/II Study
1963 Single
Institute Analysis of Reduced Intensity Cord Blood Transplantation from
Unrelated Donors for Adults with Advanced Lymphoid Malignancies
1964
Encoraging Results after Alternative Donor Transplantation for Myelodysplastic
Syndrome
1965 Interest
of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell
Lymphoma: A Multicenter Retrospective Study
1966 Stem
Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia (ALL)
in First Complete Remission (CR1)
1967
Unrelated Cord Blood Transplantation after Nonmyeloablative Conditioning :
Single Institutional Retrospective Comparison with Bone Marrow or Peripheral
Blood Stem-Cell Transplants
1968 Donor
Characteristics Affecting Graft Failure and Survival after Unrelated Donor
Transplantation with Reduced Intensity Conditioning Regimens (RIC) for
Hematologic Malignancies
1969 Cord
Blood (CB) Unit Mononuclear Cell (MNC) Dose: Effect on Transplantation Outcome
and Relevance to Processing Method and CBU Selection
1970
Reduced-Intensity Unrelated Cord Blood Transplantation in Adult – a Single
Center Analysis of 318 Transplants
1971
Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and
Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An
Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem
Cell Transplantatioin (SCT)
1972 Double
Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or
Reduced Intensity Conditioning: Report of the SFGM-TC Registry
1973 Rapid
NKG2D Reconstitution on NK Cells Possibly Plays a Major Role in the Development
of Graft-Versus-Leukemia Effect in the Early Period after Unrelated Cord Blood
Transplantation
1974
Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell
Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma:
Results of a Randomized Phase II Study
1975 Single
Donor 4/6 Matched Banked Unrelated Cord Blood Is An Effective Graft Source for
Children Undergoing Myeloablative Transplantation for Malignant and Nonmalignant
Disorders: Single Center Analysis of 318 Patients
1976
Engraftment Syndrome Following Unrelated Cord Blood Transplant in Pediatric
Patients
Biologic Therapies for NHL (Excluding Pre-clinical Models)
1997
Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic
Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in
Complete or Partial Remission
1998 Safety
in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Results
from Phase IIIb MAXIMA Trial
1999
Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial
2000 Effect
of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy
in Patients (pts) with Non Hodgkin's Lymphoma (NHL): Analysis of SWOG Clinical
Trials
2001 Phase II
Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as
First-Line Treatment for Follicular Lymphoma: An Update and Extension of
Preliminary Findings on Predictors of Relapse
2002 Extended
Follow-up of the International Randomized Phase 3 First-Line Indolent Trial
(FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®)
Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s
Lymphoma
2003
Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell
Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes
after R-CHOP Chemotherapy
2004 A Phase
II Trial of Combination Bortezomib (Velcade®) and Rituximab for Untreated “High
Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)
2005 Phase
I Results of Combination Gemcitabine and Bortezomib (Velcade®) for
Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive
B-Cell NHL (B-NHL)
2006
Prognostic Value of Early 18fluorodeoxyglucose PET Scan in Patients with Diffuse
Large B Cell Lymphoma Treated with Rituximab Plus CHOP or High-Dose CHOP
2007
First-Line Treatment with Rituximab Combined with Intravenous or Oral
Fludarabine for Patients with Extranodal Mucosa Associated Lymphoid Tissue
(MALT) Lymphoma
2008 A
Cumulative Series from 14 Western Countries Suggests That Rituximab
Significantly Changed the Dismal Natural History of Intravascular Large B-Cell
Lymphoma (IVL)
2009
Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients
with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Preliminary
Results of a Prospective Study of the Intergruppo Italiano Linfomi and Roche
(ML18324)
2010
Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell
Leukemia/Lymphoma
2011
Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with
Waldenstrom’s Macroglobulinemia
Clinical Care - Recurrence, Secondary Neoplasia, and Late Complications after
Transplantation
2130
Obesity in Survivors of Childhood Hematopoietic Stem Cell Transplantation
2131
Pre-Transplant Bone Status Evaluation in Patients Undergoing Allogeneic Stem
Cell Transplantation
2132
Long-Term Immune Deficiency (ID) after Allogeneic Stem Cell Transplantation (allo-SCT)
Following a Myeloablative (MA) Conditioning Regimen
2133
Longitudinal Trends in Peripheral Blood Parameters Predict Development of
Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/AML) after
Autologous Transplantation for Lymphoma
2134
Quantification by Superconducting Quantum Interference Device (SQUID) of Iron
Overload after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
2135 Bone
Complications Following Allogeneic Hematopoietic Stem Cell Transplantation: A
Single-Center Prospective Study
2136
Pulmonary Function in Pediatric survivors of non-Malignant Disorders after
Allogeneic Hematopoietic Stem Cell Transplantation
2137 Late
Pulmonary Dysfunction in Long-Term Survivors after allogeneic
Hematopoietic Stem Cell Transplantation with Intensified Conditioning Regimen
Including Thiotepa, Cyclophosphamide, and Total Body Irradiation
2138 High
Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients
2139 The
Prevalence of 25-Hydroxyvitamin D Deficiency in Post-HSCT Pediatric Patients
2140 Genomic
Instability Is Frequent in Oral and Rare in Nasal Mucosal Cells of Allogeneic
HCT Recipients
2141 Efficacy
of Imatinib Mesylate in the Treatment of Refractory Sclerodermatous Chronic
Graft-Versus-Host Disease
2142 Long
Term Follow-up and Matched Pair Analysis of Adjuvant Donor Lymphocyte
Transfusions Following Allogeneic Stem Cell Transplantation after Reduced
Intensity Conditioning for High-Risk AML
2143
5–azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+
Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic
Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell
Transplantation
2144 The
Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts
Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing
Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations
2145
High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients
with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year
Follow-up Experience
2146 Long
Term Outcomes for Patient with Diffuse Large B-Cell (DLBCL) or Hodgkin's
Lymphoma (HL) following Autologous Stem Cell Transplant (ASCT) Who Are Disease
Free at Five Years Post Transplant
2147
Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell
Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell
Transplantation (HCT)
2148 Isolated
Extra-Medullary Relapse of Acute Leukemia after Allogeneic Stem-Cell
Transplantation; Different Kinetics and Better Prognosis Than Systemic Relapse
2149
Treosulfan Compared to Total Body Irradiation-Based Preparative Regimens Before
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia : A
Retrospective Long-Term Study
Clinical Care - Transplantation Regimen Toxicities and Engraftment
2150
Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well
Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor
Activity against Non-Remission Hematologic Malignancies Including AML
2151 Cost
Analysis of Mobilization and Autologous Transplantation in Patients Who Received
AMD 3100 after Failing Standard Mobilization
2152
Relationship of Targeted Busulfan Exposure to Engraftment in Children Undergoing
Myeloablative Matched Sibling Donor Transplantation for Sickle Cell Disease
2153 Outcomes
of Allogeneic Stem Cell Transplant in Patients with Myeloid Leukemias Over 65
Years of Age. Rationale for Aggressive Therapy with Curative Intent
2154 Novel
Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in
Patients with Chronic Myeloid Leukemia
2155
Non-Relapse Mortality (NRM) after Autologous Stem Cell Transplant (ASCT) Is
Reduced with Stringent Follow-up Post-Transplant
2156 Possible
Role of Engraftment Syndrome in Myelodysplastic Syndrome after Autologous
Transplants
2157 Impact
of Donor/Recipient Major ABO Mismatch on Allogeneic Transplantation Outcome
According to Stem Cell Source: Results from An 809-Patient Retrospective Study
2158
Monitoring of Post-Transplant Hematopoiesis in Patients Receiving
High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of
Detection of Remarkable Abnormalities
2159 Delayed
Platelet Engraftment and Early Increased Creatinine after Stem Cell Transplant
Predicts Sustained Remission in Pediatric Leukemia
2160
CD8-Depleted Donor Lymphocyte Infusions Convert Mixed into Complete Donor T-Cell
Chimerism after T-Cell Depleted Allogeneic Stem Cell Transplantation
2161 An
Analysis of Toxicities and Time to Engraftment Associated with Three Distinct
Melphalan Treatment Schemas in Patients with Multiple Myeloma Receiving
Autologous Hematopoetic Stem Cell Transplantation
2162
Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative
Conditioning for Patients (pts) Aged ≥60 Years
2163
Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing
Reduced-Intensity Versus Full-Intensity Transplants
2164 No
Impact of Postremission Consolidation Chemotherapy Before Allogeneic Transplant
in Patients with First Remission Acute Myeloid Leukemia with Intermediate or
High Risk Cytogenetics
Clinical Results - Allogeneic Matched Related Donor Transplantation
2165
Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT)
for Patients with High-Risk Multiple Myeloma (MM): A Survey from the Societe
Francaise De Greffe De Moelle Et De Therapie Cellulaire
2166
Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using
Myeloablative Versus Reduced Intensity Conditioning: Long-Term Follow-up
2167 Higher
Absolute NK Count on Day30 after HLA Identical Sibling Allogeneic Stem Cell
Transplantation and a “Favorable KIR” Genotype Are Associated with Faster NK
Maturation and Other Functional Differences
2168 Similar
5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA
Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia
(AML) in First Complete Remission (CR1)
2169
Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling
Transplants for Older Patients with Severe Aplastic Anemia (SAA)
2170
Attainment of Minimal Residual Disease Negative State Is Crucial for Successful
Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation
in Advanced Chronic Lymphocytic Leukemia (CLL)
2171 Updated
Results of JALSG AML201 Study Comparing Intensified Daunorubicin with Idarubicin
in Patients with De Novo Acute Myeloid Leukemia: Effect of Hematopoietic Stem
Cell Transplantation
2172
Incidence of Late Failure Following Myeloablative Conditioning with BuCy2 and
Matched Sibling Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
2173
Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell
and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic
SCT
2174
Chimerism and Tolerance after Combined Human Kidney and Hematopoietic Cell
Transplantation Using Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte
Globulin
Clinical Results - Autologous Transplantation
2175
Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count
Following Autologous Hematopoietic Stem Cell Transplant in Patients with
Non-Hodgkin’s Lymphoma and Multiple Myeloma
2176 BuCy
Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in
Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (≥60
years) Patients
2177
Prognosis Value of [18f] FDG-PET Prior Versus after Autologous Stem Cells
Transplantation in High Grade Non-Hodgkin’s Lymphoma
2178 The Role
of FDG-PET in Hodgkin Lymphoma S/P Autologous Hematopoietic Cell Transplant
(HCT) as a Predictor of Outcome
2179 Outcome
of Transplant-Eligible Patients with Hodgkin Lymphoma with An Inadequate
Response to Second Line Chemotherapy with Gemcitabine, Dexamethasone, Cisplatin
(GDP)
2180 Early
Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict
Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in
Hodgkins Disease and Non-Hodgkins Lymphoma
2181 HIV
Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation
(ASCT) for B Cell Non Hodgkin Lymphoma (NHL)
2182 Impact
on Progression Free Survival of Autologous Stem Cell transplantation after
Consolidation with Alemtuzumab in Chronic Lymphocytic Leukemia
2183 15 Year
Follow-up of ABMT for NHL: Surprisingly Favorable Outcome for Younger Adults
2184 Length
of Stay among Patients Undergoing Autologous Stem Cell Transplantation for
Lymphoma:Predictive Factors and Prognostic Effect
2185 Long
Term Molecular Remissions after Autologous Haematopoietic Stem Cell Transplant
in Follicular Lymphoma
2186
Superior Survival in Non-Hodgkin Lymphoma Following Autologous Stem Cell
Transplantation with Intravenous Busulfan, Cyclophosphamide, and Etoposide
2187 Red
Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90 Y - Ibritumomab
Tiuxetan
2188
Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation
Predicts Superior Event Free Survival of Patients with Relapsed or Refractory
Hodgkin Lymphoma
2189 Impact
of Autologous Stem Cell Transplantation and/or Rituximab on Outcome of Patients
with Relapsed Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials
of the German Low Grade Lymphoma Study Group (GLSG)
2190
Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma
Patients: A Long-Term Retrospective Study
2191 High
Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression
Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using
Patients as Their Own Controls
2192
Fludarabine, but Not Mitoxantrone, Increases the Risk of a Poor Stem Cell
Harvest and Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous
Leukemia (tMDS/AML) after Autologous Stem Cell Transplantation (ASCT) in
Patients with Follicular Lymphoma (FL)
2193
Achievement a Negative 18-FDG/PET Status at the End of Procedure by Tailored
Treatment According Pre-Transplantation Pet Status in Lymphomas Improve 5
Years-OS and EFS
2194 Phase
I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning
Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent
and Refractory Hodgkin Lymphoma
Clinical Transplantation – Acute and Chronic GVHD, Infectious Complications,
and Immune Reconstitution
2195
Hemorrhagic Cystitis and BK Virus Infection in Children after Hematopoietic Stem
Cell Transplantation
2196 IFN-γ
Induced by PHA Stimulation as New Marker for Gvhd Prediction in Patients
Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
2197
Reactivation of Cured Hepatitis B Virus after Allogeneic Hematopoietic Stem Cell
Transplantation and Its Asociation with Liver Graft Versus Host Disease
2198
Identification of New Minor Histocompatibility Antigens (mHags) in Patients with
Chronic Graft Versus Host Disease (GvH) after Allogeneic Stem Cell
Transplantation by SEREX
2199
Predominant Reconstitution of B Lymphoid Precursors (Hematogones) Following
Unrelated Cord Blood Stem Cell Transplantation
2200 Risk
Factors and Survival Analyses of Ocular Graft-Versus-Host Disease (GVHD) in the
Current Era of Allogeneic Stem Cell Transplant (SCT)
2201 The
Impact of NOD2/CARD15, TLR and IL23R Polymorphisms on the Incidence of
Infectious Complications in Allo-HSCT Recipients
2202 Analysis
of a New graft–versus‑host Disease (GvHD) Prophylaxis Regimen with Additional
Enteric‑coated Mycophenolate Sodium (EC‑MPS) Starting 10 Days after Unrelated
Allogeneic Stem Cell Transplantation
2203 Phase I
Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell
Transplantation
2204
Reconstitution of Regulatory T Cells Involves in the Development of Acute
Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation
2205 Clinical
Significance of Autoantibody Expression in Allogeneic Stem Cell Recipients
2206 The
Promising Strategy of Mycophenolate Mofetil Dosing to Prevent Moderate- to
Severe-Acute Graft-Versus-Host Disease
2207
Multivirus-Specific T Cell Immunotherapy to Prevent or Treat Infections of Stem
Cell Transplant Recipients
2208
HHV6-Associated Limbic Encephalitis after Reduced-Intensity Umbilical Cord Blood
Transplantation
2209
Association of Mannose Binding Lectin (MBL-2) Deficiency with Pulmonary
Infection after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
2210 High
Overall Response Rate in Calcineurin Inhibitor-Free Treatment with the mTOR
Inhibitor Everolimus in Advanced Extensive Chronic GvHD after Allogeneic Stem
Cell Transplantation
2211
Significantly Reduce Acute Graft-Versus-Host Disease in Haploidentical Stem Cell
Transplantation by Using Cord Blood as the Third Party Cells
2212
Evidence of a Significant Contribution of Thymic Output to T Cell Reconstitution
Following Full Haplotype Mismatched Stem Cell Transplant (HSCT) Leading to a
Predominantly Naïve Phenotype
2213
Cytomegalovirus (CMV)-Specific CD8+ T Cells Are Associated with Control of Viral
Reactivation Post-Hemopoietic Stem Cell Transplantation (HSCT) Only If Shown to
Be Functionally Active
2214 Use of
the Tetanus Toxoid, Reduced Dose Diphtheria and Pertussis Vaccine (Tdap) in
Allogeneic Transplant (alloHCT) Recipients
2215
Clinical Outcome of Aspergillus-Specific Cytotoxic T Lymphocytes for Refractory
Invasive Aspergillosis in Patients with Hematological Malignancies
2216
Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High-Resolution
HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic
Hematopoietic Stem Cell Transplantation
2217
Assessment of Durability of Response in Patients with Skin Graft Versus Host
Disease beyond Six Months Treatment with Extracorporeal Photopheresis: Reduction
of Steroid Resistance and Evaluation of Long-Term Therapy on Survival
2218 The
Effect of Donor Lymphocyte Infusion Dose on the Occurrence of Severe
Life-Threatening Acute Graft-Versus-Host Disease Early after Reduced Intensity
Conditioning T Cell Depleted Stem Cell Transplantation
2219
Association of Treatment with Sirolimus (SIR) and Calcineurin Inhibitor (CNI)
for Prevention or Treatment of Graft-Vs-Host Disease (GVHD) with Transplant
Associated Microangiopathy (TAM)
2220 Early
Lymphocyte Recovery Predicts Superior Survival after Unmanipulated
HLA-Mismatched/Haploidentical Blood and Marrow Transplantation for Patients with
Hematological Malignancies
2221
Comparison of Immune Reconstitution after Unmanipulated HLA-Mismatched/
Haploidentical Blood and Marrow Transplantation and Unmanipulated HLA-Matched
Sibling Transplantation in Patients with Hematological Malignancies
2222
Universal CD137 Expression upon Activation Allows Efficient Isolation of a Broad
Repertoire of Virus-Specific CD8+ and CD4+ T Cells for Adoptive Immunotherapy
2223
Improved Overall Survival in Patients Recovering with High Gamma/Delta T Cells
after Allogeneic Haematopoietic Stem Cell Transplantation
2224
Reactivation of Human Herpes Virus 6 (HHV6) during Hematopoietic Stem Cell
Transplantation: Risk Factor Analysis of HHV6 Encephalitis and Survival
2225
Generation of Combined CD8+ and CD4+ T Cell Lines with High Specificity for
Adenovirus Hexon Epitopes for Adoptive Immunotherapy after Allogeneic Stem Cell
Transplantation
2226
Increase in Proportion of Th-17 Lymphocytes in Blood Heralds Overt Acute Graft
Versus Host Disease in HSCT Patients
2227 Donor
Type Impacts the Incidence of Severe Acute but Not Chronic Graft-Versus-Host
Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell
Transplantation (ASCT) for Treatment of AML/MDS
2228
Plasmacytoid CD123+ Dendritic Cell Recovery Is An Independent Predictor of
Survival after Unrelated Cord Blood Transplant (UCBT)
2229
Cyclosporine a and Mycophenolate Mofetil Vs Cyclosporine a and Methotrexate as
Gvhd Prophylaxis in Reduced Intensity Conditioning Hematopoietic Stem Cell
Transplantation from HLA-Identical Sibling Donor
2230 The
Influence of Cytochrome P450 3A Gene Polymorphisms on Tacrolimus Concentrations
in Hematopoetic Stem Cell Transplantation Patients
2231
Increased Type I Interferon Signaling and Inflammatory Factors Associated with
T-Bet+ Cytotoxic Effectors in Chronic Graft Versus Host Disease of Oral Mucosa
2232
Rituximab Prophylaxis of EBV Reactivation after Alternative Donor Transplants
Following Anti-Thymocyte Globulin-Based Conditioning Regimens
2233 Early
Prediction of Acute Gvhd Based on Molecular Profiling at the Time of Engraftment
after Hematopoietic Stem Cell Transplantation
2234
Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses
While Recipient Plasma Cells Persist
2235 A
Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis
Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate:
Analysis of GVHD, Relapse and Survival
2236 The
Distribution of KIR Gene in Chinese Population and the Effect of Donor KIR and
Patient HLA Genotypes on Outcome Following Allogeneic Hematopoietic Stem Cell
Transplantation
2237 The FcγRllla
Polymorphism Correlates with Chronic Graft-Versus-Host Disease and Treatment
Related Mortality
2238
Functional Control of CMV Reactivation Is Profoundly Influenced by CMV
Serostatus after Nonmyeloablative Hematopoietic Cell Transplantation Following a
TLI-ATG Preparative Regimen
2239
Re-Evaluation of Chronic Graft-Versus-Host Disease Using National Institute of
Health Consensus Criteria
2240
Comparison of Cyclosporine and Methotrexate with Cyclosporine and Mycophenolate
Mofetil for Gvhd Prophylaxis in Myeloablative Allogeneic Bone Marrow
Transplantation
Experimental Transplantation - Basic Biology, Immune Function, and
Engraftment
2317
Sensitization to Minor Histocompatibility Antigens Poses a Barrier in
Transplantation and Can Be Prevented by CD154:CD40 Co-Stimulatory Blockade
2318
CD8+/TCR- Facilitating Cells Induce Generation of Regulatory T cells in Vivo:
Chimeric Regulatory T Cells are Antigen-Specific and Enhance Engraftment of
Allogeneic HSC in Non-Obese Diabetic (NOD) Mice
2319 Fully
Functional NK Cells Promote Graft-to-Leukemia Effect, after Cord Blood
Transplantation
2320
Horizontal Gene Transfer through Apoptotic Bodies Confers a Possible Mechanism
of Epithelial Chimerism after Allogeneic Hematopoietic Cell Transplantation
2321
Co-Transplantation of MSC Improves the Engraftment of HSC after Auto-iBMT in
Non-Human Primates
2322
Humanized Sc(Fv)2 Minibody against C-Mpl Successfully Increased Platelet Number
in Monkey and Increased Engraftment of Human Umbilical Cord Blood Cells in
NOD/SCID Mouse
2323 Ex-Vivo
Acquisition of Central Memory Phenotype Is Critical for Tolerance Induction by
Donor Anti-3rd party CD8 T Cells in Allogeneic Bone Marrow Transplantation
2324 Ex Vivo
Expansion and Long-Term Hematopoietic Reconstitution Ability of Sorted
CD34+CD59+ Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria
2325
Interaction with Human Stromal Cells Enhances CXCR4 Expression and Engraftment
of Cord Blood Lin-CD34- Cells Via Wnt Signaling
2326 Dose and
Timing Limitations in the Use of Bone Marrow-Derived Mesenchymal Stem Cells for
the Treatment of Experimental Arthritis
2327
5-Androstene-3b,17b-Diol Administration of Mice Exposed to Total Body
Irradiation Results in Rapid Reconstitution of Immature Bone Marrow Progenitor
Cells and Synergizes with Thrombopoietin but Not with Granulocyte-Colony
Stimulating Factor
2328 A Novel
SNP-Based Method for Assessing Langerhans Cell Chimerism Following Hematopoietic
Stem Cell Transplantation in Humans
2329 siRNA-Induced
Transient Silencing of PTEN Expression Enhances Human Hematopoietic Cell
Engraftment in NOD/SCID/γcnull Mice and Increases Gene Transduction Efficiency
2330 Control
of the HSC Niche Signaling for the Efficient Long-Term Engraftment of
Hematopoietic Stem Cells without Irradiation or High-Dose Chemotherapy
2331
Cyclosporine, but Not mTOR Inhibitors, Hampers the Reconstitution of Bone
Marrow-Derived Tregs in Long-Term Complete Donor chimeras
2332
Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a
Liposomal Formulation of KRN7000 (RGI-2001)
2333 Compared
to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced
Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells
2334 In Vivo
Development of Murine NK Cells Early after Congeneic BMT: Effects of MHC
Molecules, and the Administration of hIL-15
2335 The
Antioxidant Inflammation Modulator, CDDO-Me Promotes Myelopoiesis in Mice
2336
Conversion to Full Donor Chimerism without Gvhd Using High-Dose DLI in Minimally
Conditioned Miniature Swine Recipients of Haploidentical HCT
2337
Pharmacological Inhibition of EGFR Signaling Enhances G-CSF Induced
Hematopoietic Stem Cell Mobilization
Experimental Transplantation - GVHD and GVL
2338
Graft-Versus-Host Tolerance in Dogs Following T-Cell Depleted Bone Marrow
Transplantation with Absorbed ATG or CD6-Antibody
2339
UTY-Coded Minor Histocompatibility Antigens as Targets for a Graft-Versus-Host
Reaction against Hematopoietic Cells in the Dog
2340 TCRbeta
Gene Rearrangements for Detection and Monitoring of Minimal Residual
Disease after Allogenic Stem-Cell Transplantation in Patients with Advanced
Mycosis Fungoides and Sézary Syndrome
2341
Roscovitine Prevents Alloreactive T Cell Expansion and TNF-a-Mediated
Proinflammatory Gene Expression and Protects against GvHD
2342 Donor T
Cell Production of IL-21 Accelerates Graft-Versus-Host Disease Lethality
2343
Paradoxical Effects of Interferon-γ in Allogeneic Bone Marrow Transplant: Donor
Dendritic Cells Regulate Graft-Versus-Leukemia and Graft-Versus-Host Disease
Activities
2344 Large
Scale Selective Ex Vivo Expansion of CD4+CD25+FOXP3+ Regulatory T Cells from
Peripheral Blood
2345 Donor
Bone Marrow Derived IL-17 Expressing Cells Exacerbate Chronic Graft-Versus-Host
Disease in a Murine Bone Marrow Transplantation
2346
Peripheral Alloantigen Drives Early Dysfunction and Eventual Exhaustion of CTL
Following Delayed Donor Leukocyte Infusions
2347 GITR
Ligand on Leukemic Myeloid Dendritic Cells Suppresses Induction of
Leukemia-Associated Antigen-Specific CTLs from Naïve CD8+ T Cells
Lymphoma: Chemotherapy and Clinical Trials Poster II
2585 A
Prospective Multicenter Phase II Study by the Puget Sound Oncology Consortium
(PSOC) of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R)
in Patients with Relapsed/Refractory Lymphoma
2586 Phase II
Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and
Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated
Patients with Relapsed/Refractory Hodgkin Lymphoma (HL)
2587
Incidence, Predictors and Significance of Severe Toxicity in Patients with
HIV-Associated Hodgkin Lymphoma
2589
Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell
Lymphoma
2590 Long
Term Follow-up of the GELF86 French and Belgian Trials :
Complete Remission after First Line Treatment with Conventional Chemotherapy in
Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall
Survival Compared with Partial Remission
2591
Chemotherapy Alone for Localized Non-Bulky HOODGKIN Lymphoma
2592 PET-CT
Adapted Therapy after 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma.
Interim Analysis. Preliminary Results in 102 Patients
2593 Relapse
after Autologous Stem Cell Transplant (ASCT) for Diffuse Large B Cell Lymphoma:
Clinical Outcome and Prognostic Factors Affecting Long-Term Outcome
2594 BEACOPP
Chemotherapy Is Able to Induce Durable Complete Remission in Poor-Prognosis
Hodgkin’s Lymphoma Patients with a Positive Interim PET after 2 ABVD Cycles
2595 A Phase
II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory
Classical Hodgkin Lymphoma (cHL): Preliminary Results
2596
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the
First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell
Lymphomas: Results of a Randomized Phase III Study of the Studygroup Indolent
Lymphomas (StiL)
2597
Hodgkin’s Lymphoma(HL) in Tunisia Results of a 5 Year Prospective
Multicenter Trial in 251 Pts
2598 A
Prospectively Randomized Placebo-Controlled Trial of Epoetin-α in Patients with
Advanced-Stage Hodgkin Lymphoma: Final Analysis of the GHSG HD15-EPO Trial
2599
Rituximab in Combination with CHOP in Patients with Follicular Lymphoma:
Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of
the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months
2600 The
Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in
Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the
German Hodgkin Study Group (GHSG)
2601
Rituximab Plus Gemcitabine, Ifosfamide, Oxaliplatin (R-GIFOX), a New Effective
Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Hodgkin
Lymphoma
2602 Long
Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs
MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A
Study from the Intergruppo Italiano Linfomi (IIL)
2603 Late
Relapse of Localized High-Grade Non-Hodgkin's Lymphoma: Clinical and Biological
Features
2604
Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define
Groups of Patients with Different Overall Survival Which Cannot Be Entirely
Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population
Based Study of the Scotland and Newcastle Lymphoma Group
Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster II
2605
Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the
Treatment of Human Lymphomas
2606
Stimulation of T Cells by Lenalidomide Involves Putative Lenalidomide Binding
Proteins CD3-Epsilon-Associated Protein and GDP-Mannose Pyrophosphorylase a
2607 The
Acquirement of Rituximab Resistance Is Associated with a Global Downregulation
of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in
Rituximab Anti-Tumor Activity
2608
Prolonged Inhibition of BCR Signaling and Suppression of B Cell Lymphoma through
Irreversible Inhibition of Bruton's Tyrosine Kinase
2609
Enzastaurin Displays Activity against Follicular Lymphoma Cells : Role of mTOR
Pathway
2610
Synergistic and Persistent Effect of T-Cell Immunotherapy with Anti-CD19 or
Anti-CD38 Chimeric Receptor on B-Cell Lymphoma in Conjunction with Rituximab
2611 The
Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-1 Kinase
Inhibitor Protein RKIP) in B-NHL Via Inhibition of the Transcription Repressor
Snail : Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis
2612 Direct
Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of
Non-Hodgkin Lymphoma Cells Are Associated with Increased SPARC Expression
2613
Inhibition of NF-Kb Cell Signaling and Induction of the Metastasis Suppressor
and Immune Surveillance Cancer Gene RKIP Expression in B-NHL by the Novel
Humanized BM-Ca Anti-CD20 Monoclonal Antibody: Implication in Chemo and
Immune-Sensitization
2614 PKC412,
a Small Molecule Tyrosine Kinase Inhibitor, Regulates Survival and Proliferation
Pathways in Waldenstrom Macroglobulinemia
2615 The
Tyrosine Kinase Src Regulates Adhesion and Survival in Waldenstrom
Macroglobulinemia
2616
Lenalidomide Enhances Anti-Tumor Effect of γδ T Cells against Mantle Cell
Lymphoma
2617
Regulation of Histone Deacetylase in Waldenstrom Macroglobulinemia
2618
Development and Therapeutic Potential of An Anti-CD79b Antibody-Drug Conjugate,
Anti-CD79b-Vc-MMAE, for the Treatment of Non-Hodgkin's Lymphoma
2619
Development of Vaccine-Based Immunotherapy for Murine Large B-Cell Lymphoma
2620 The
“Side-Population” of Human Lymphoma Cells Have Increased Chemo-Resistance,
Stem-Cell Like Properties and Are Potential Targets for Immunotherapy
2621
XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent
in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell
Malignancies
2622
Characterization and Novel Treatment for Therapy-Resistant Mantle Cell Lymphoma
Isolated from Liver and Kidney
2623
Generation of CD8 T Cell-Mediated Protective Immunity against Tumor Escapees
2624 The
Functional Impact of PKCß/PI3K/AKT Signalling on Translational Initiation in MCL
Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy Poster II
2812 Serum
Concentration of L-Kynurenine Can Determine Clinical Outcome of Patients with
Diffuse Large B-Cell Lymphoma Treated with R-CHOP
2813
Abnormalities in Serum Free-Immunoglobulin Light Chains Show a High and
Differential Frequency among WHO Subtypes of B-Cell Non-Hodgkin’s Lymphoma (NHL)
and May Turn of Value for Therapeutic Monitoring: A Study of 354 Newly Diagnosed
Patients
2814
Translocations Involving 8q24 in Burkitt Lymphoma and Other Malignant Lymphomas:
A Historical Review of Cytogenetics in the Light of Todays Knowledge
2815 Combined
FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall
Survival and Risk of Transformation in Uniformly Treated Patients with
Follicular Lymphoma
2816 Human
T-Cell Leukemia Virus Type 1 Tax Activates Caveolin-1 Gene Expression
2817
Significance of Serum Soluble IL-2R in DLBCL and FL Is Different from That in
ATL
2818 Gene
Expression Profiling Reveals a Crucial Role for C/EBPbeta in Proliferation
Pathways of ALK+ ALCL Cell Lines
2819 Diffuse
Large B-Cell Lymphoma (DLBCL) Patients with Composite Histology Have Improved
Early Outcome Compared to De Novo DLBCL When Treated with R-CHOP
2820 T-Cell
Receptor Signaling Proteins, BCL10 and Phosphorylated-P65 NF-KB, Are Expressed
in Peripheral T-Cell Lymphomas and Associated with Clinical Outcome
2821 Clinical
Significance of Serum TARC/CCL17 in ATLL Patients: High TARC/CCL17 Level Is a
Significant Unfavorable Prognostic Factor
2822 Extended
Focal Imaging Reveals An Improved Gauge of Angiogenic Activity and Highlights
the Role of Angiogenesis in Survival and Time to Transformation in Follicular
Lymphoma
2823
EBV-Negative Post-Transplant Lymphoproliferative Disorder (PTLD): A
Retrospective Case-Control Study of Clinical and Pathological Characteristics,
Response to Treatment and Survival
2824
Assessment of Microrna Expression in Mantle Cell Lymphoma Using High Throughput
Techniques
2825
Migratory Activity and Stromal Cell Adhesion of Mantle Cell Lymphoma Cells Can
Be Diminished by Blocking of VLA-4 and CXCR4 Receptors
2826 CD74 Is
a Regulator of Fas-Mediated Apoptotic Signaling
2827
Expression, Role in Transformation and Prognostic Significance of the
Transcription Factor Yin Yang 1 (YY1) in Non-Hodgkin’s Lymphoma: Analyses in NHL
Tissues by Experimental and Bioinformatic Approaches
2828
Validation of Mantle Cell International Prognostic Index (MIPI) in Mantle Cell
Lymphoma (MCL) in a Retrospective Single Institution Series
2829
Neuroinflammatory and Neurodegenerative Markers in Non-Hodgkin’s Lymphoma and
Hematologic Malignancies with Central Nervous System Involvement
2830 Relapsed
MALT Lymphomas Are Associated with a Restricted VH3-30.3 Immunoglobulin VH Gene
Repertoire and Are Targeted by Aberrant Somatic Hypermutation
2831
Circulating Antibodies to ALK Inversely Correlat with Relapse Risk and
Circulating Tumor Cells in Children and Adolescents with ALK-Positive Anaplastic
Large Cell Lymphoma
2832 FLIPI
and F2 Index – Prognostic Indices in Advanced Stage Follicular Lymphoma
2833 Central
Nervous System (CNS) Relapse in Extranodal NK/T Cell Lymphoma, Nasal Type: When
Do We Need CNS Prophylaxis in Patients with Extranodal NK/T Cell Lymphoma?
2834
Proportions of Bone Marrow Lymphocyte Subsets Predict Survival in Patients with
Newly Diagnosed Diffuse Large B-Cell Lymphoma Independent of International
Prognostic Index
2835
Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron
Emission Tomography ([18F] FDG-PET/CT) in Aggressive T-Cell Lymphomas
2836
Prognostic Impact of Microvessel Density in Follicular Lymphoma Patients Treated
with Immunochemotherapy
New and Emerging Biologic Therapies of NHL
229
Post-Transplant Lymphoproliferative Disorder: Evaluation of Effectiveness of
Reduction of Immunosuppression or Systemic Chemotherapy
230 Complete
Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T
Lymphocytes Targeting EBV Latent Membrane Proteins
231
Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and
Relapsed Hodgkin's Lymphoma
232 Serious
Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal
Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer
and Leukemia Group B (CALGB) 50502
233 Phase I
Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed
and Refractory Non-Hodgkin’s Lymphoma
234 A Phase
I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+
Malignant Disease
235 Idiotype
Vaccination of Untreated Indolent B-Cell Lymphoma: Durable Objective Remissions
and Association of Superior Outcome with Cellular Immune Responses
236 A
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with
Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+
Follicular Lymphoma
Targeted Therapies and New Agents in Lymphoma
261
PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with
Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or
Refractory Peripheral T-Cell Lymphoma
262
Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in
Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An
International Study (NHL-003)
263
Clinically Significant Responses Achieved with Romidepsin in
Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B,
International, Multicenter, Registration Study
264
Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET
Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma
265 VcR-CVAD
Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A
Phase II Study from the Wisconsin Oncology Network
266 Safety
and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin
(CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large
B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study
267 Sustained
Response Duration Seen after Treatment with Single Agent Blinatumomab
(MT103/MEDI-538) in the Ongoing Phase I Study MT103-104 in Patients with
Relapsed NHL
268
Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in
Patients with Relapsed or Refractory Diffuse Large-B-Cell Lymphoma: Results of
An International Study (NHL-003)
Clinical Results - Allogeneic Matched Related Donor Transplantation I
343 Lower
Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger
Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?
344
Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation
for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies
345 Impact of
Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC)
Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling
for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)
346 Non-Myeloablative
Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS:
Results from the Center for International Blood and Marrow Transplant Research
(CIBMTR)
347
Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with Acute Myelogenous
Leukemia (AML). Final Analysis of JALSG AML97 Study
348 Similar
Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative
Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for
International Blood and Marrow Transplant Research
Mantle Cell Lymphoma, Follicular Lymphoma, Tumor Microenvironment
373 The
Mir-17~92 Cluster Enhances Cell Growth and Resistance to Chemotherapy in Mantle
Cell Lymphoma by Down-Regulating PTEN, PHLPP2 and BIM
374 Protein
Profiling of Plasma Membranes and Lipid Rafts Defines Aberrant Signaling
Pathways in Mantle Cell Lymphoma
375
Agricultural Pesticide Use  and the T(14;18) Connection to Lymphomagenesis
376 MUM1
Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients
Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone
(SWOG 8809): A Southwest Oncology Group Correlative Science Study
377
Signaling Diversity in Human Lymphoma B Cells and in Tumor Infiltrating T Cells
Correlates with Follicular Lymphoma Patient Clinical Outcomes
378 Monocytes
Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are
Recruited to the Tumor Microenvironment by CCL5 (RANTES)
Clinical Results - Allogeneic Matched Related Donor Transplantation II
457
Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from
the Lymphoma Working Party of the EBMT
458 Reduced
Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results
in An Improved Progression Free Survival When Compared to Autologous Stem Cell
Transplantation. An Analysis from the Lymphoma Working Party of the EBMT
459 Non-Myeloablative
Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients
Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell
Non-Hodgkin Lymphoma (NHL)
460 RIC
Allogeneic Transplantation Improves the Overall and Progression-Free Survival of
Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO
Retrospective Study Based on Time of HLA-Typing and Donor Availability
461 Donor
Versus No Donor Analysis of Newly Diagnosed Myeloma Patients Included in the
HOVON 50/54 Study
462 Efficacy
of Allogeneic Hematopoietic Stem Cell Transplantation during First Complete
Remission Following Imatinib-Combined Chemotherapy in Patients with Philadelphia
Chromosome-Positive Acute Lymphoblastic Leukemia
Diffuse Large B-cell Lymphoma: Biology and Prognosis
475
Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis
in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma
476 Biologic
Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose
Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study
477 Deletion
in Chromosome 17p12 and Gains in Chromosome 9q33.3 by Array Comparative
Hybridization Are Associated with R-CHOP Treatment Failure in Patients with
Diffuse Large B Cell Lymphoma
478 Array-CGH
Identifies Regions, Including the FOXP1 Locus, Associated with Different
Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP
479
Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable
Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP
480 The
Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome
and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21
Clinical Studies in Lymphoma
577 The
Impact of the Association of Vinblastine during Induction Chemotherapy and as
Maintenance Treatment in Children and Adolescents with High-Risk Anaplastic
Large Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group
578
Sequential Evaluation of Outcome in Enteropathy Associated T Cell Lymphoma
Comparing Standard Therapeutic Approaches – Surgery or CHOP-Like Chemotherapy
with a New High Dose Ifosfamide / Methotrexate and Autologous Stem Cell
Transplant Regimen: A Prospective Study of Scotland and Newcastle Lymphoma Group
579 A
Prospective Phase II Trial of An L-Asparaginase Containing Regimen in Patients
with Refractory or Relapsing Extra Nodal NK/T-Cell Lymphoma
580
Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate
Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS
Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival
Analysis
581 RCHOP and
RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell
Lymphoma (MCL) : Final Results of a Phase II Study from the GELA
582
Molecular Remission after Combined Immunochemotherapy Is of Prognostic Relevance
in Patients with MCL: Results of the Randomized Intergroup Trials of the
European MCL Network
583 Statin
Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B
Cell Lymphoma (DLBCL)
584 The Role
of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two
Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group
(DSHNHL) for Elderly Patients with DLBCL
DLBCL and Other NHL: Novel Therapeutic Targets and Approaches
601
Interleukin-21 Induces Cell Cycle Arrest and Apoptosis of Diffuse Large B-Cell
Lymphomas (DLBCL) Via Activation of STAT3 and Upregulation of C-Myc
602 Antitumor
Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell
Lymphoma
603 Histone
Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive
Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation
in Diffuse Large B-Cell Lymphoma
604
Onco-Mir-155 Targets SHIP to Regulate TNF-Dependent B-Cell Lymphoma Growth
605 The
BH3-Mimetic Obatoclax (GX15-070) Posses a Dual-Mechanism of Action and Induces
Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin’s
Lymphoma (B-NHL) Cells
606 MLN4924,
a Novel Small Molecule Inhibitor of Nedd8-Activating Enzyme, Demonstrates Potent
Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma
607
Epigenetic Silencing of BIM Mediates Chemotherapy Resistance of Patients with
Burkitt Lymphoma That Can Be Overcome by Therapeutic Reactivation of BIM in
Mouse and Human Lymphoma Models
608 Gene
Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in
Human and Mouse Models of Mantle Cell Lymphoma
Low Grade B-cell Lymphoma: Biology
617 Gene
Expression Profiling of Post-Follicular B-Cell Lymphoma
618
Comprehensive Analysis of the Waldenström Macroglobulinemia “Cytokine Milieu”
Reveals a Novel Role of Rantes Signaling in the Regulation of Immunoglobulin
Production
619 TRAF3
and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in
Waldenström’s Macroglobulinemia
620 miRNA
Analysis Identifies a Unique Expression in Waldenström Macroglobulinemia B Cells
and Plasma Cells
621 High
Resolution Array-Based Analysis in Marginal Zone Lymphomas and Lymphoplasmacytic
Lymphomas Identified Disease-Specific Patterns of Chromosome Abnormalities
622 Array-CGH
Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone
Lymphomas
623
Immunoglobulin Gene Repertoire in Ocular Adnexa Lymphomas (OAL): Hints on the
Nature of the Antigenic Stimulation
624 Mir-21
Is Over Expressed in Aggressive SMZL
Alternative Donor Transplantation Poster III
2993
Donor/Recipient Mixed Chimerism Does Not Predict Graft Failure in Children with
Beta-Thalassemia Given Allogeneic Cord Blood Transplantation from An
HLA-Identical Related Donor
2994 A
Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell
Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with
Low Treatment-Related Mortality
2995 Dose
Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a
Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell
Transplantation in Patients with Advanced Aggressive Non-Hodgkin Lymphoma: An
Interim Analysis of a Phase I/II Study
2996 Cord
Blood (CB) Extends Transplant Access to Racial and Ethnic Minorities: A
Prospective Study of 309 Unrelated Searches in Patients with High-Risk
Hematologic Malignancies
2997 The
Comparison Between Matched Related Donor and Alternative Donor for Allogeneic
Hematopoietic Stem Cell Transplantation in Patients with Acquired Aplastic
Anemia: KSBMT2007-02 Study
2998
Alternate Donor HCT for Fanconi Anemia (FA): Results of a Total Body Irradiation
(TBI) Dose De-Escalation Study
2999
Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic
Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th
Decades of Life with AML or MDS
3000 Platelet
Recovery Prior to Stem Cell Transplantation Predicts for Post-Transplant
Outcomes in Patients with AML
3001 The
Effect of the CASP8 -6526N Del Promoter Polymorphism on Outcome in T-Cell
Depleted Unrelated Donor Haemopoetic Stem Cell Transplants (HSCT)
3002
Anti-Leukemia Activity of Alloreactive NK Cells in Haploidentical HSCT in
Pediatric Patients: Re-Defining the Role of Activating and Inhibitory KIR
3003 Perfect
Engraftment after Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning
Regimen for Unrelated Transplantation in Severe Aplastic Anemia: Phase II
Prospective Multi-Center Study in Korea
3004
Contribution of HLA Incompatibility on Clinical Outcomes of CBT in Patients with
MDS Including Secondary AML in Japan: Multivariate Analysis Using Competing Risk
Regression Model
3005
Mismatching at HLA-DPB1 Is Not Associated with Survival in Patients with
Acquired Aplastic Anemia Who Receive Unrelated Bone Marrow Transplantation
3006 Impact
of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Tansplant for
Children with AML beyond the First Complete Remission: Total Body Irradiation
Versus Busulfan- a Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Study
3007
Insufficient Evidence for Association of NOD2/CARD15 or Other Inflammatory Bowel
Disease-Associated Markers with Gvhd or Other Outcomes in T-Replete, Unrelated
Donor Transplantation Facilitated by the NMDP
3008
Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based
Reduced Intensity Unrelated Donor Allogeneic Transplantation
3009
Graft-Vs-Leukemia Effects of Allogeneic Stem Cell Transplantation from HLA-Haploidentical
Family Members as Compared to HLA-Identical Sibling Donors
3010 Effects
of Recipients' Body Weight and Total Nucleated Cell Dose on Outcomes of
Unrelated Bone Marrow Transplantation: Analysis of Clinical Data of 3,114
Leukemia Patients from the Database of the Japan Marrow Donor Program
3011 TGFB1
Functional Polymorphisms: Impact on Outcome in Allogeneic Unrelated Donor
Haematopoietic Stem Cell Transplantation
3012
Identifying Amino Acid Substitution Positions Associated with Day 100 Survival
in Unrelated Donor Stem Cell Transplant Using Random Forest Analysis
3013 The
Presence of Moderate to High Donor-Specific Anti-HLA Antibody Titers Is
Associated with a High Risk of Graft Failure in Haploidentical Stem Cell
Transplantation
3014
Theoretical Availability of UCBT in High Body Weight Patients Who Received Haplo-SCT
for High Risk Haematological Malignancies: Results of the Simulation of Search
through BMDW According to International Guidelines
3015
Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for
Patients Lacking HLA Identical Donors
Biologic Therapies for NHL (Excluding Pre-clinical Models) Poster III
3048 A
Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with
Relapsed/Refractory Classical Hodgkin Lymphoma
3049 The
Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior
Response Rates, Time to Treatment Failure and Response Duration in Patients with
Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG
Trial
3050
Rituximab Plus Hypercvad Alternating with High Dose Methotrexate and Cytarabine
for Patients with Newly Diagnosed Mantle Cell Lymphoma. A Multicenter Trial from
GISL
3051 Phase I
Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and
Cytarabine for Untreated Mantle Cell Lymphoma
3052 Phase II
Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
3053 A Phase
II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with
Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma
3054 A
Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin
after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis
C Virus (HCV) Infection
3055
Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab (177LU-D-R): A Phase
I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other
Indolent B-Cell Lymphomas
3056 R-FND
Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma
3057 Long
Term Responses to Fludarabine and Rituximab in Waldenstrom's Macroglobulinemia
3058
Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo
Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle
Cell Lymphoma
3059 Phase
I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for
Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin’s Lymphoma:
Feasibility and Initial Safety
3060 R2:
Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in
Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL)
3061 90y
Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS
Protocol). An Italian Cooperative Study Group
3062 A
Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for
Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type
3063
Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary
Gastric Non Hodgkin Lymphoma
3064
Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell
Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the
International RIT-Network
3065
Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in
Symptomatic Patients with Waldenstrom's Macroglobulinemia (WM) Treated with
Cladribine (2-CdA) Combination Induction Therapy
3066
Evaluation of Humoral Immune Responses to Vaccination with Tetanus Toxoid and
KLH in Rituximab-Treated Follicular Non-Hodgkin’s Lymphoma Patients Compared to
Healthy Volunteers
Clinical Results - Allogeneic Matched Related Donor Transplantation Poster
III
3291
Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute
Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal
Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial
3292
Successful Long- Term Outcome and Chimeric Status Following Allogeneic Stem Cell
Transplantation for Non-Malignant Disorders Using Moderate T Cell Depletion with
No Post Transplant Gvhd Prophylaxis
3293
Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia
Transformed from Myelofibrosis
3294
Reduced-Intensity Conditioning for Allograft (RICT) after Cytoreductive
Autograft (ASCT) in Relapsed/Resistant Hodgkin’s Lymphoma (HL)
3295
Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Acute Lymphoblastic
Leukemia: Better Outcome in Transplantation during First Complete Remission and
with Myeloablative Conditioning
3296
HLA-Matched Sibling Stem Cell Transplantation Using Conditioning Regimen with
Reduced Dose of Cyclophosphamide, ATG and Fludarabine in Patients with Severe
Aplastic Anemia
3297 Addition
of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC)
Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced
Hematologic Malignancies
3298
Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the
Outcome in Advanced Multiple Myeloma
3299 Tandem
Autologous-Nonmyeloablative (NMA) Allogeneic(Allo) Transplant (Tx) in Newly
Diagnosed Multiple Myeloma (MM) Leads to Improved Survival When Compared to
Conventional Allogeneic Transplant
3300 Natural
Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic
Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation
3301
Cytomegalovirus Drives Acute Myeloid Leukemia Cells in Apoptosis and Reduces
Thereby Markedly the Risk for Relapse after Transplant
3302 Stem
Cell Transplantation in Remission Improves Survival in Acute Myelogenous
Leukemia Associated with FLT3 Mutations
3303
Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving
Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell
Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo
Italiano Trapianto Di Midollo Osseo (GITMO)
3304 Low
Dose Alemtuzumab Achieves Long-Term Engraftment with Low Level Mixed Chimerism
in Related Haemopoietic Stem Cell Transplantation for Haemoglobinopathies
3305 Impact
of Comorbidity Index on Outcome with Allogeneic Hematopoetic Stem Cell
Transplantation for Chronic Lymphocytic Leukemia
3306 Outcome
of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular
Ejection Fraction
3307 Use of
Reduced Intensity Conditioning (RIC) Regimens Are Associated with a Better
Outcome with Sibling Donors Transplants in Older Patients (> 50 years) with
Acute Myeloid Leukemia (AML)
3308
KIR/HLA-I Mismatching Predicts Risk of Relapse in Pediatric Patients Undergoing
Allogeneic Hematopoietic Stem Cell Transplantation
3309
Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloblastic
Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Patients (pts) Older Than 50
Years: a Retrospective Single Center Study
3310
Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using
Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte
Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with
Retained Anti-Tumor Activity
Clinical Results - Autologous Transplantation Poster III
3311
Higher Incidence of Relapse with Peripheral Blood Rather Than Marrow as a Source
of Stem Cells in Adults with Acute Myelocytic Leukemia, but Not in Adults with
Acute Lymphocytic Leukemia Autografted during the First Remission
3312 12
Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for
Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients
with Multiple Myeloma
3313
Autologous Transplantation Is the Optimum Approach to the Management of Myeloma
Patients with Extramedullary Disease at Presentation
3314 Standard
Consolidation /Maintenance Chemotherapy Is Consistently Superior to a Single
Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia:
Results of the International ALL Trial (MRC UKALL XII / ECOG E2993)
3315 Steroid
Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for
Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with
Multiple Myeloma (MM)
3316
Melphalan 200 Mg/m2 (Mel200) Versus Melphalan 100 Mg/m2 (Mel100) in Newly
Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study
3317 Double
Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation
with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma
3318
Autologous Stem Cell Transplantation in Patients with Autonomic Neuropathy Due
to AL Amyloidosis
3319
Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic
Features into Prognostic Scoring at Point of Autologous Stem Cell
Transplantation for Multiple Myeloma
3320 A
Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic
Trioxide with or without Bortezomib in Multiple Myeloma
3321
Prognostic Value of Bone Marrow Angiogenesis in Patients with Multiple Myeloma
Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
3322 Lack of
HLA Class I Ligands for Autologous Inhibitory KIR Is Associated with Improved
Survival Following Autologous Stem Cell Transplant for Children with
Neuroblastoma
3323
Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients
with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell
Transplantation
3324 A High
Long-Term Survival Were Produced by Early Sequential Intensive Consolidation
Chemotherapy Followed by Autologous Stem Cell Transplantation in First Complete
Remission in Patients with Adult Acute Lymphoblastic Leukemia
3325
Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as
Frontline Therapy for Non-Transplant Candidates in Patients with Previously
Untreated Multiple Myeloma
3326 Total
Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T)
Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts)
with Multiple Myeloma (MM)
3327 Outcome
of African-American (AA) Multiple Myeloma (MM) Patients after Autologous Stem
Cell Transplantation (ASCT): A Single-Center Experience
3328 Outcome
of Patients with IgD and IgM Multiple Myeloma Undergoing Autologous
Hematopoietic Stem Cell Transplants: A Retrospective CIBMTR Study
3329 Early
Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for
Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune
Recovery but Improved Responses and Overall Survival
3330
Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib,
Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with
Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib
for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial
3331
Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Benefit
from the Newer Drugs Used in the Relapsed Setting
3332 A
Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for
Autologous Transplant for Myeloma: The Effect of Sequence of Administration
3333 Effect
of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation
(Auto HCT) for Multiple Myeloma (MM): An Analysis from the Center for
International Blood and Marrow Transplant Research (CIBMTR)
3334
Improvement of Long-Term Survival after High-Dose Melphalan in Patients with
Light Chain Amyloidosis Responding to Induction Chemotherapy
3335
Superior Incidence of Progression-Free Survival (PFS) Following High-Dose
Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma
(MM) Patients Receiving Pre-Transplant Induction with IMiDs Versus Conventional
VAD Induction Chemotherapy
Experimental Transplantation - GVHD and GVL Poster III
3499
Induction of Invariant NKT Cell-Dependent Alloreactivity by Administration of
G-CSF after Bone Marrow Transplantation
3500 A
Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality
through the Expansion of CD4+Foxp3+ Regulatory T Cells in Murine Models
3501 Induced
CD4+CD25+ FOXP-3+ and CD8+CD25+ FOXP-3+t Cells Exhibit a Concurrent Expression
of Effector and Selective Suppressive Capacities
3502 Potent
Activation of Healthy Donor T-Cells Specific for Mantle Cell Lymphoma
Immunoglobulin Derived Peptides by CD40- and TLR7/8-Ligand Matured Dendritic
Cells in Vitro
3503
Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic
Transplantation:Mediators for Gvl Effects?
3504
HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1
Specific T Cell Responses Showing Immunogenicity of All HLA-DPB1 Alleles
3505
Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated
from Umbilical Cord Blood for Adoptive Immunotherapy
3506
Recruitment of Donor T Cells to Secondary Lymphoid Tissue Is Enhanced by
Conditioning Therapy and Donor T Cells/Marrow
3507 Lack of
“Bystander” Activation and Evidence for Competition for Resources among Gvh-Reactive
CD4 T Cells
3508 Host
Environment Determines the Development of Gvhd but Not the Extent of Activation
and Expansion of Gvh-Reactive CD4 T Cells
3509
Redundant Mechanisms for Dendritic Cell Activation in GVΗD Induction: Signalings
Via TLRs, TNF-α, IL-1 and CD40 Are Not Required
3510 Soluble
Lymphotoxin Plays a Critical Role in Acute Graft-Versus-Host Disease
3511
Recipient Langerhans Cells Are Neither Required Nor Sufficient for GVΗD
Induction in MHC-Matched Allogeneic BMT, but a Langerin+ Cell Is a Pivotal
Regulator of Langerhans Cell Turnover Post Transplantation
3512
Disruption of Gamma Interferon Signaling through the STAT1 Pathway Enhances
Alloreactivity While Abrogating GvHD
3513 SOCS3
Regulates Th1 Dependent Acute Graft-Versus Host Disease
3514 Donor T
Cells Lacking IFN-Gamma Receptor Expression Enhance Donor Myeloid Engraftment
and Decrease Early Acute Graft-Versus-Host Disease Mortality Following
Allogeneic Bone Marrow Transplantation
3515
Lentiviral Engineered T Regulatory Cells Effectively Inhibit Lymphocytes
Alloreactivity across Major HLA Barriers
3516 Only
MHC-Identical Donor CD4+CD25+ Regulatory T Cells Convey Full Protection from
Lethal Graft-Versus-Host Disease
3517 Vß
Spectratype-guided Separation of Graft-Versus-Host Disease and
Graft-Versus-Leukemia Effects in a MHC-Matched miHA-Mismatched Mouse Model of
Hematopoietic Stem Cell Transplantation
3518
Cytolytically Defective Tregs Can Prevent Spontaneous Autoimmune Disease and
Gvhd, but Fail to Suppress Autochthonous Lymphoproliferation
3519 A Novel
Approach to Prevent GvHD: Donor Cells Engineered to Display on Their Surface a
Recombinant Form of FasL Protein Effectively Prevent Lethal GvHD in a Mouse
Model
3520 Use of
R-spondin1, An Intestinotrophic Mitogen, in the Treatment of Murine
Graft-Versus-Host Disease
3521
Flagellin, a TLR5 Agonist, Down-Regulate CD62L on Donor T Cells and Limit GvHD
in Allogeneic Hematopoietic Stem Cell Transplantation
3522
Prevention of Acute GvHD during Haplo-BMT: Evaluating the Efficacy of T-Cell
Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model
3523
Composition and Persistence of Donor Cell Infiltrates in Host Target Organs
Instigate the Development of Chronic Graft-Versus-Host Disease
Lymphoma: Chemotherapy and Clinical Trials Poster III
3586
VNCOP-B (Etoposide, Mitoxantrone, Cyclophosphamide, Vincristine, Prednisolone,
Bleomycin) Plus Rituximab Therapy in Elderly Patients with Aggressive B-Cell
Non-Hodgkin Lymphoma: A Phase II Study of Efficacy and Safety
3587
Liposome-Encapsulated Doxorubicin Is Highly Active in Patients with B- as Well
as T/ NK-Cell Lymphomas and Cardiac Comorbidity or Older Age
3588 The
Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy
PET Scan in Previously Untreated Patients with Histologically Aggressive
Non-Hodgkin Lymphoma (NHL)
3589 Poor
Outcome for Children and Adolescents with Progressive Disease or Relapse of
Lymphoblastic Lymphoma - a Report of the BFM Group
3590 Gray
Zone Lymphomas: Clinical and Histological Characteristics and Treatment with
Dose-Adjusted-EPOCH-R
3591
Treatment of Primary CNS Lymphoma in the Elderly, a Multicenter Retrospective
Analysis
3592
Treatment of High Grade B-Cell Lymphoma with Chemotherapy Plus Rituximab: A
Survival Benefit Can Be Demonstrated in the Routine Data of a Regional Cancer
Registry
3593
Intensified CHOP (ICHOP) +/- Rituximab in Primary Mediastinal Diffuse Large B
Cell Lymphoma (PMBCL): The Role of Doxorubicin/Cyclophosphamide Dose-Intensity
3594
High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Primary CNS
Lymphoma: Updated Results from a Pilot and Phase II Study
3595
Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive
Burkitt Lymphoma
3596 The
Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy
(IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS
Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically
Controlled Prospective Study
3597 High
Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed
Patients with Mantle Cell Lymphoma Treated with R-MACLO-IVAM-T
3598 Effect
of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to
Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage
Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)
3599 A Phase
II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP
Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma
3600
Long-Term Disease Control in Patients with Primary Central Nervous System
Lymphoma
3601
Treatment Outcome and Prognostic Factors in Patients with Precursor B and T
Lymphoblastic Lymphoma
3602 Relapse
of Central Nervous System Lymphoma after systemic Lymphoma (SCNSL): Clinical
Features and Outcome as compared to Primary CNS Lymphoma (PCNSL) Patients
3603 Treating
Lymphoma with Curative Intent in HIV Positive Patients after the Advent of
HAART: A Comparative Analysis with the HIV Negative Population
3604
R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell
Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score
2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study
Including 160 Patients Aged 18-64 Years
3605
Importance of Relative Dose Intensity for Survival in Diffuse Large B-Cell
Lymphoma Patients Treated with CHOP-Like Regimen
3606
Long-Term Outcome of AIDS-Related Lymphoma Treated with Abbreviated Cycles of
EPOCH-RR: A Prospective Study of 40 Patients
3607 Interim
18f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell
Lymphoma
3608 The
Impact of Therapeutic Management and Prognostic Factors on the Outcome
of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study)
3609
Gem-(R)CHOP Versus (R)CHOP: A Randomized Phase II Study of Gemcitabine Combined
with (R)CHOP in Untreated Aggressive Non-Hodgkin’s Lymphoma - EORTC Lymphoma
Group Protocol 20021
3610
High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3
Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma.
Results of the Randomized Arms of COG A5971
3611
High-Dose Methotrexate and Cytarabine Chemotherapy May Be Effective and Safe in
Solid Organ Transplant Recipients with Primary CNS Lymphomas (PCNSL)
3612
Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An
Effective Therapy for HIV-Associated Burkitt’s Lymphoma (BL)
3613
Reduction of Immunosuppression and Subsequent Rituximab Monotherapy or
CHOP-Based Chemotherapy +/- Rituximab as a Treatment for PTLD Does No Impair the
Renal Graft Function: A Matched Pair Control Analysis in 55 Renal Transplant
Recipients with PTLD and 1075 Renal Transplant Controls
3614 Results
of the Largest Study on Post-Transplant-Lymphoproliferations (PTLDs) of the
Central Nervous System (CNS) in the Rituximab Era: A Surprising
Overrepresentation of Kidney Transplantations, Key Importance of Methotrexate (Mtx),
Cytarabine (AraC) and Radiotherapy (RX) for Long Term Survival and Low Impact of
Rituximab (R)
3615 No
Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal
Diffuse Large B-Cell Lymphoma
3616 THP-COP
Regimen for the Treatment of Peripheral T Cell Lymphoma and Adult T Cell
Leukemia/Lymphoma: A Multicenter Phase II Study
Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy Poster III
3742
PI3K/AKT-and JAK3-Dependent Regulation of SKP2 Expression Is Mediated by E2F1 in
Anaplastic Large Cell Lymphoma
3743 NT-ProBNP
Is the Strongest Prognostic Factor for Survival in Lymphoma Patients Following
Treatment with Curative Intent
3744 Use of
MicroRNA Expression Profiling to Identify Prognostic Subclasses in Mantle Cell
Lymphoma: Mir-29 Family as New Prognostic Markers
3745 Mantle
Cell Lymphoma International Prognostic Score Is Valid and Confirmed in
Unselected Cohort of Patients Treated in Rituximab Era
3746 The
Stage-Specific Effect of Interleukin-1 Beta (IL-1β) during Human Natural Killer
Cell Development
3747 Neither
CD68+ Nor CD163+ Macrophages Are Associated with Decreased Survival in
Follicular Lymphoma
3748
Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) Is Expressed in Low
Grade NHL and B-CLL and Activates the Non Canonical Wnt Pathway
3749 IgA and
IgG Hypogammaglobulinemia Is a Constitutive Feature in Most Waldenstrom’s
Macroglobulinemia Patients and May Be Related to Mutations Associated with
Common Variable Immunodeficiency Disorder (CVID)
3750
Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL)
3751 Role of
Human Endogenous Retroviruses in Lymphoma Pathogenesis and a Possible Biomarker
of Disease
3752
High-Throughput Cloning of T(11;14) Breakpoints Outside the Major Translocation
Cluster in Mantle Cell Lymphoma
3753
Incidence Clinical Characteristics and Survival of Non Splenic Marginal Zone
Lymphomas: A Population Based Study from a Cancer Registry in Northern Italy
3754
Lymphomas in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy: A
Report from the Swedish Biologics Register (ARTIS) and the ARTIS Study Group
1998-2006
3755 Early
Response Using Serum Immunoglobulin Free Light Chain (sFLC) Measurement Predicts
Response to Therapy in Waldenstrom Macroglobulinemia (WM)
3756 A
Prognostic Role for Absolute Lymphocyte Counts in Pediatric Non-Hodgkin's
Lymphoma
3757
Identification of Huntingtin Interacting Protein 1 Related (HIP1R) as a Novel
Lymphoma Autoantigen Using Antigen Array Profiling
3758
Immune-Related and Inflammatory Conditions Likely Play a Role in the Development
of Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia
3759
Sequential Chemotherapy Followed by High Dose Therapy and Autologous Stem Cell
Rescue for Mantle Cell Lymphoma: Impact of MIB-1 on Outcome
3760
Regulation of p27 by S-Phase Kinase- Associated Protein 2 Is Associated with
Aggressiveness in Diffuse Large B Cell Lymphoma (DLBCL)
3761
Aberrant Co-Expression of Key Transcription Factors BCL6, IRF4 and FOXP1 Are
Frequently Observed in Diffuse Large B-Cell Lymphoma
3762 Genetic
Variation in Genes That Regulate T-Cell Differentiation and Function Is
Associated with An Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma
3763 Mirna
Profiling Reveals Specific Patterns for Normal B Cell Subsets and B Cell
Lymphomas with a Unique Burkitt Lymphoma Profile
3764
Marginal Zone Lymphoma: Factors That Affect the Final Outcome, a Study of 275
Patients
3765
Distinct Role of Src Family Kinase Inhibitors in Burkitt Lymphoma Cells Vs.
Diffuse Large B-Cell Lymphoma Cells
3766
Epidemiological and Clinico-Pathological Features of Systemic Peripheral T-Cell
Lymphomas (PTCL): A Population-Based Analysis from the Danish Lymphoma Registry
LYFO
3767
Lymphoma-Expressed VEGF-a, VEGFR-1, VEGFR-2, and Microvessel Density Are Not
Predictive of Overall Survival in Follicular Lymphoma
3768 Risk of
Hepatitis B Virus (HBV) Reactivation and Role of Anti-Viral Prophylaxis in
Lymphoma Patients with Past HBV Infection (HBV Antigen negative but
anti-Hepatitis B core antibody positive) Receiving Chemo-Immunotherapy
3769 LMO2
Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell
Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study
3770
Identification of Differentially Expressed Genes in the Rituximab-Resistant
Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications
in Rituximab-Resistance
3771 Higher
Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower
Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study
3772 Are
Mast Cells a Biologic Predictor of Outcome in Follicular Lymphoma?
3773 Human
Herpesvirus 8 Protein K1 Interferes with Fas-Mediated Apoptosis Induces Clonal
Growth and Lymphoid Hyperplasia
3774
Arachidonic Acid Metabolism-Related Molecules as Candidate Markers in
Subclassification of Lymphoma
3775 CD4
Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with
Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Independent of the aaIPI
3776
Networking Modules of Canonical and Alternative NFkB Signaling in Growth and
Survival Regulations of Large B Cell Lymphomas
3777
Follicular Non-Hodgkin Lymphoma Grade 3a and 3b Subtypes Exhibit Similar
Clinical Behaviour and Treatment Outcome
3778
CD4+Foxp3+ Regulatory T Cells Persist in High Numbers in Peripheral Blood after
Induction of Clinical Remission with Standard Chemotherapy and Suppress
Tumor-Specific Effector T Cells in Patients with Follicular Lymphoma
3779
High-Throughput Sequencing for Diagnosis, Prognosis and Monitoring of Lymphoid
Malignancies
3780
Distinct Patterns of Systemic Immune Dysregulation in Indolent B Cell Lymphoma
3781 From
Signalosome to Enhanceosome: The Translocation of CD40 from Membrane to Nucleus
Involves Multiple Mechanisms
3782
Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma
Patients Treated with R-CHOP
3783 The
Impact of Rituximab Resistance on Overall Survival Rate in Low-Grade Follicular
Lymphoma
Autologous Transplantation: Lymphoma
769 Early
Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem
Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term
Follow up of a Randomized Trial of the
770 High-Dose
Chemotherapy Followed by Autologous Stem Cell Transplantation (auto-SCT) Versus
CHOP Regimen in Patients with Untreated Aggressive Non-Hodgkin’s Lymphoma: An
Update of the GOELAMS 072 Trial with a Median Follow-up of 9.8 Years
771 Survival
Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large
B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative
Autotransplantation (HDC) : A GELA Phase II Study
772
Autologous Stem Cell Transplantation after Myeloablative Therapy in First
Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma
after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of
the German Low Grade Lymphoma Study Group (GLSG)
773
Autologous Stem Cell Transplantation (auto-SCT) as the Treatment of Choice for
Follicular Lymphoma Patients in First Relapse: Final Analysis of the Outcome of
175 Patients Treated in the GELA/GOELAMS FL 2000 Study
774 Patients
with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and
Autologous Stem Cell Transplantation
775
Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant
Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory
Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047
776
Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is
Essential for Predicting Outcome in Patients with Transplant-Eligible Relapsed
and Primary Refractory Hodgkin Lymphoma
Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment
2
793
Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC)
Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute
Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of
EBMT
794 Second
Unrelated Donor (URD) Transplant as a Rescue Strategy for 122 Patients with
Primary Non Engraftment: Results from the CIBMTR
795
Fludarabine Exposure Is Associated with Increased Treatment Related Mortality
after Nonmyeloablative Hematopoietic Cell Transplantation (HCT)
796
Age-Dependent Pharmacokinetic Profile of Single Daily Dose Intravenous Busulfan
in Children Undergoing Reduced-Intensity Conditioning Stem Cell Transplantation
797
Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis
Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched
Unrelated Donor
798
Comparative Assessment of Weighting Comorbidities in the Hematopoietic Cell
Transplantation (HCT) Specific Comorbidity Index (HCT-CI)
799 Busulfan
and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on
Nonrelapse Mortality in Patients with AML/MDS
800
Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) Is Accompanied by
Endotoxemia, Activation of Endotoxin-Directed Innate Immunity, and Deficiency of
Endogenous Proteins That Limit Endotoxin-Induced TNF Production
Diffuse Large B-cell Lymphoma: Molecular Biology
801
Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse
Large B-Cell Lymphoma
802 BCL6
Regulates Tonic BCR Signaling in Diffuse Large B-Cell Lymphomas by Repressing
the SYK Phosphatase, PTPROt
803 Gene
Expression Profile Analysis According to Recurrent Gene Copy Number
Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by
9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA
Study
804
Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under-Reported
and Clinical Outcome Depends on the MYC Partner
805
Differentiation-Stage-Specific Expression of MicroRNAs in B-Lymphocytes and
Diffuse Large B-Cell Lymphomas (DLBCL)
806 MicroRNA
Is Prognostic Indicator in Patients with Diffuse Large B Cell Lymphoma
807
Genome-Wide Analysis of B Cell Non-Hodgkin’s Lymphoma Disclosed Frequent
Involvement of Genes in NFkB Pathway
808 A
Population of Suppressive Monocytes Inhibiting T Cell Proliferation and
Dendritic Cell Differentiation in Relapsed Non-Hodgkin's Lymphoma
Incorporation of Rituximab into Clinical Management of NHL
832 Phase
II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or
Refractory Waldenstrom Macroglobulinemia
833 Rituximab
(R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years:
Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma
(MCL)
834 Brief
Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in
Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of
a Prospective Randomized IIL Trial
835
Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates
in Indolent B-Cell Lyphoma without Prolonged Myelosuppression
836 Rituximab
Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma:
Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
837
Rituximab Fails to Reduce Histologic Transformation (HT) Rate of Follicular
Lymphoma (FL) to Diffuse Large B-Cell Lymphoma (DLBCL)
838 Safety,
Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB
Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin
Lymphoma (B-NHL): A Children’s Oncology Group Report
839 The
Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL
Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas
Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the
Mabthera International Trial Group (MInT) Study
Preclinical Studies in NHL: Novel Antibodies and Immunotherapeutic Approaches
880
I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell
Non-Hodgkin's Lymphoma
881 An Fc-Engineered
Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in
Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and
Multiple Myeloma
882 Cyclin D1
as a Universally-Expressed Mantle Cell Lymphoma-Associated Tumor Antigen for
Immunotherapy
883 Novel
Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab)
and HLA-DR Monoclonal Antibodies
884 Cancer
Stem Cell Activity in Mantle Cell Lymphoma Is Inhibited by TLR9 Activation
885
Lenalidomide Repairs Suppressed T Cell Immunological Synapse Formation in
Follicular Lymphoma
886
Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody
Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma
887
Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein
Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell
Lymphoma Cells